Результаты поиска

Lipocalin 2-not only a biomarker: a study of current literature and systematic findings of ongoing clinical trials.

Lipocalin 2 (Lcn2), also known as neutrophil gelatinase-associated lipocalin, is an innate immune protein encoded by the LCN2 gene. In this study, we investigated various roles and functions of Lcn2 characterized in a systems-based format and evaluated its therapeutic potentials and clinical relevance for diagnosis and prognosis. An additional systematic presentation was presented for 70 ongoing clinical trials utilizing Lcn2 in the diagnostic and prognostic setting as a key outcome measure. With trials being conducted through December 2030, Lcn2 will become all the more relevant given its ass

Совпадение в полном тексте источника
… ; withdrawal; reduction | Drug: prednisolone; drug: sulfasalazine; drug: leflunomide; drug: methotrexate; drug: tofacitinib; drug: apremilast; drug: etanercept; drug: adalimumab; drug: infliximab; drug: certolizumab pegol; drug: golimumab; drug: abatacept; drug: secukinumab; drug: ixekizumab; drug: ustekinumab …

Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review.

Haematological malignancies induce important alterations of the immune system, which account for the high frequency of autoimmune complications observed in patients. Cutaneous immune-mediated diseases associated with haematological malignancies encompass a heterogeneous group of dermatoses, including, among others, neutrophilic and eosinophilic dermatoses, autoantibody-mediated skin diseases, vasculitis and granulomatous dermatoses. Some of these diseases, such as paraneoplastic pemphigus, are associated with an increased risk of death; others, such as eosinophilic dermatoses of haematological

Совпадение в полном тексте источника
… Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. Clin Exp Dermatol. 2019;44:116–119. doi: 10.1111/ced.13679. 71. …

The JAK/STAT signaling pathway: from bench to clinic.

The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular processes, the JAK/STAT pathway constitutes a rapid membrane-to-nucleus signaling module and induces the expression of various critical mediators of cancer and inflammation. Growing evidence suggests that dysregulation of the JAK/STAT pathway is associated with various cancers and autoimmune diseases. In this review, we discuss the current knowledge about the composition, activation, and regulation of the JAK/STAT pat

Совпадение в полном тексте источника
… attenuates chronic graft-versus-host disease in murine models of lupus nephritis. 342 P40 mAb has been tested in many diseases in preclinical studies, such as psoriasis and Crohn’s disease. 343 , 344 The results of phase 3 clinical trial including 312 adults with active psoriatic arthritis (PsA) show that ustekinumab …

Antibodies to watch in 2022.

In this 13th annual installment of the annual 'Antibodies to Watch' article series, we discuss key events in commercial antibody therapeutics development that occurred in 2021 and forecast events that might occur in 2022. Regulatory review of antibody therapeutics that target the SARS-CoV-2 coronavirus proceeded at an unprecedented pace in 2021, resulting in both emergency use authorizations and full approvals for sotrovimab, regdanvimab, REGEN-COV2, as well as others, in numerous countries. As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the Un

Совпадение в полном тексте источника
… Action on the application has thus been deferred until the inspections can be completed. 56 The decision to grant a marketing approval in the EU was supported by results from three Phase 3 studies that included an active comparator arm, ustekinumab (Stellara®; BE VIVID study; NCT03370133 ), adalimumab …

Cytotoxic CD4+ T cells: origin, biological functions, diseases and therapeutic targets.

Cytotoxic CD4+ T lymphocytes are a unique subset of CD4+ T cells characterized by their cytokine secretion and cytolytic activity. Unlike traditional CD4+ helper T cells, cytotoxic CD4+ T lymphocytes exhibit similar cytotoxicity to that of CD8+ T cells, revealing unexpected plasticity in CD4+ T-cell functions. This flexibility suggests that CD4+ T cells can transform and acquire effector functions beyond their conventional functions, emphasizing their importance in various immune responses. Despite the identification of cytotoxic CD4+ T lymphocytes decades ago, recent advancements have broaden

The journey of boswellic acids from synthesis to pharmacological activities.

There has been a lot of interest in using naturally occurring substances to treat a wide variety of chronic disorders in recent years. From the gum resin of Boswellia serrata and Boswellia carteri, the pentacyclic triterpene molecules known as boswellic acid (BA) are extracted. We aimed to provide a detailed overview of the origins, chemistry, synthetic derivatives, pharmacokinetic, and biological activity of numerous Boswellia species and their derivatives. The literature searched for reports of B. serrata and isolated BAs having anti-cancer, anti-microbial, anti-inflammatory, anti-arthritic,

Совпадение в полном тексте источника
… These include immune suppressive drugs (alefacept) and anti-cytokine treatments TNF therapies (adalimumab, etanercept, infliximab, and ustekinumab) (Papoutsaki and Costanzo 2013 ). Alternatively, to treat psoriatic and eczematous symptoms, anti-inflammatory molecules can be applied topically. …

Регулирование на основе Virobiome микробиота-гут-мозговой оси сигнализирует и нейроиммунный гомеостаз.

Ось человеческого кишечника все чаще признается как сложная двунаправленная коммуникационная система, объединяющая микробные, нейронные, эндокринные и иммунные сети, формирующие неврологическое здоровье. Хотя бактериальный вклад в этот диалог получил широкую окраску, вирусный компонент кишечной экосистемы, виром, стал важным компонентом, связанным с физиологическим регулированием принимающей стороны. В этом обзоре обобщены данные, свидетельствующие о том, что бактериофаги и эукариотические вирусы могут способствовать микробному и иммунальному гомеостазу и оказывать влияние на сигнализацию вдол

Совпадение в полном тексте источника
… cells | Maintains Th17 cell responses and contributes to chronic inflammation | Associated with T-cell infiltration and enhanced IL-17 production | Associated with exacerbation of autoimmune neuroinflammation in MS and EAE models | Induced by LPS and dysbiotic microbiota | Reported to be neutralized by ustekinumab …

Неделя ГЭЭ 2018 Презентации на плакате

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Antibodies to watch in 2023.

In this 14th installment of the annual Antibodies to Watch article series, we discuss key events in commercial monoclonal antibody therapeutics development that occurred in 2022 and forecast events that might occur in 2023. As of mid-November, 12 antibody therapeutics had been granted first approvals in either the United States or European Union (tebentafusp (Kimmtrak), faricimab (Vabysmo), sutimlimab (Enjaymo), relatlimab (Opdualag), tixagevimab/cilgavimab (Evusheld), mosunetuzumab (Lunsumio), teclistamab (TECVAYLI), spesolimab (SPEVIGO), tremelimumab (Imjudo; combo with durvalumab), nirsevim

Совпадение в полном тексте источника
… The randomized, placebo- and active-controlled VIVID-1 ( NCT03926130 ) is evaluating of the safety and efficacy of mirikizumab given IV and SC vs. either ustekinumab or placebo in patients with moderately to severely active Crohn’s disease. …

Structure and function of therapeutic antibodies approved by the US FDA in 2025.

In 2025, the 50th anniversary of the invention of hybridoma technology, the United States Food and Drug Administration (US FDA) approved a total of 44 new molecular entities (NMEs), of which 10 were therapeutic antibody-based molecules. Additionally, the US FDA approved 31 small molecules (of which one was a peptide), and 3 new nonantibody therapeutic proteins, but no new chimeric antigen receptor (CAR)-T-cell therapeutics. Of the new antibody-based biologics, two were antibody-drug conjugates, one was a T-cell engager-bispecific antibody, two were Fc-modified, half-life extended antibodies, a

Совпадение в полном тексте источника
… Some, such as fremanezumab [ 106 ], ustekinumab [ 107 ], eptinezumab [ 108 ], and emicizumab [ 109 ], each of which possesses a mean circulating terminal half-life in humans in the range of 27–31 days [ 3 ], have long average circulating half-lives, while at the other end of the spectrum, concizumab …

UEG Week 2015 Poster Presentations

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy.

Endoplasmic reticulum (ER) stress is a key cellular mechanism that is important in the development of many diseases, including cancer. Since the discovery of the unfolded protein response (UPR), research has greatly improved our understanding of how ER stress affects cellular functions, especially protein folding and adaptation to stress. The UPR consists of three main branches: IRE1, ATF6, and PERK, each of which is crucial for regulating stress responses, protein homeostasis, and apoptosis. These pathways normally help cells handle stress effectively; however, excessive or prolonged activati

2018 Ежегодное совещание СНГ: Североамериканская конференция по вопросам неадекватности и регулирования.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

61st Annual Conference of Indian Society of Gastroenterology, Virtual Diamond Jubilee ISGCON 2020, 19-20th December 2020.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Selected Abstracts from the 12th Annual Meeting of the Clinical Immunology Society: 2021 Virtual Annual Meeting: Immune Deficiency and Dysregulation North American Conference.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Poster Session (P001 - P578).

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 28th Европейский конгресс педиатрической ремуматологии (ПСР) 2022) Прага, Чешская Республика. 20-23 сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 2.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

10th Trends in Medical Mycology Held on 8 to 11 October 2021, Aberdeen, Scotland, Organized by the European Confederation of Medical Mycology (ECMM).

Plenary Sessions: [...].

Совпадение в полном тексте источника
… Patients have been stratified according to biologic type in either IL-17 inhibitors (secukinumab, ixekizumab, brodalumab) or IL-(12)/23 inhibitors (ustekinumab, guselkumab). Healthy subjects served as a reference control group. Immunophenotype was characterized via whole blood flow cytometry. …

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.